11/2/15-11/4/15 – Actinobac attends the BioEurope Conference in Munich, Germany.
6/22/15 – Actinobac signs technology licensing agreement with Eli Lilly Animal Health Division (Elanco).
6/15/15-6/18/15 – Actinobac attends and presents at the BIO International Conference in Philadelphia, PA.
5/10/15-5/14/15 – Actinobac attends and presents at the Cavendish Global Impact Forum in La Jolla, CA.
5/4/15-5/6/15 – Actinobac attends BioNetwork East in Miami, FL.
3/21/15 – Actinobac and Rutgers University publish a study in Leukemia Research journal demonstrating the use of Leukothera® for treatment of lymphoma.
Hematologic diseases (leukemia, lymphoma, and multiple myeloma) are cancers of white blood cells that are often deadly and difficult to treat. Preclinical efficacy studies have shown that Leukothera™ is highly effective at eliminating malignant white blood cells both under laboratory conditions and in animals.Read More
Autoimmune and inflammatory diseases comprise a range of disorders that are characterized by the abundant presence of chronically activated WBCs. Leukothera® specifically targets these activated WBCs without affecting healthy cells and tissues.Read More
HIV infects white blood cells and can hide from our immune system within them. Current therapies can target replicating virus, but do not eliminate the HIV-infected cells. These infected white blood cells are what prevent any current drugs from curing HIV infection.Read More
Crohn’s and colitis
For the millions of patients who suffer from blood cancers, autoimmune diseases, and inflammatory conditions, Actinobac offers new hope because our products specifically target and eliminate the diseased cells. This means greater benefit with fewer side effects. At Actinobac, our goal is to not just change lives, but also save them.Annual Sales of other Biologics The Path to Commercialization